Remicade vs. Inflectra: What Patients Need to Know About Switching to a Biosimilar

There are few moments in a patient’s treatment journey that feel as unsettling as being told the medication that has been keeping your disease in check is being replaced with something else. For patients who have been stable on Remicade (infliximab) — sometimes for years — receiving a letter from their insurance company or a call from their pharmacy about switching to Inflectra can trigger real anxiety. That anxiety deserves to be addressed honestly, with facts and without dismissal.

What Is a Biosimilar — and What It Is Not

The most common misunderstanding about biosimilars is that they are “generic versions” of biologic drugs. They are not, and the distinction matters.

A generic drug is a chemically identical copy of a small-molecule medication. Aspirin is aspirin — the molecular structure is simple enough that any manufacturer can reproduce it exactly.

Biologic drugs like Remicade are different. They are large, complex proteins produced by living cells. No two manufacturing processes will create absolutely identical molecules, just as no two batches of bread from different bakeries will be molecularly identical — even using the same recipe. In fact, Remicade itself varies slightly from batch to batch within the same manufacturing facility.

A biosimilar like Inflectra is a biologic product that has been demonstrated to be highly similar to the reference product (Remicade) with no clinically meaningful differences in safety, purity, or potency. It is not a generic. It is not identical. But it is close enough that the differences do not affect how it works in the body.

How the FDA Approves Biosimilars

The FDA’s approval pathway for biosimilars is demanding. Inflectra (infliximab-dyyb, manufactured by Pfizer) went through a rigorous, multi-step evaluation process:

1. Analytical studies: Detailed laboratory comparison of the protein structure, purity, and biological activity of Inflectra versus Remicade
2. Animal studies: Toxicity assessments to evaluate safety signals
3. Clinical pharmacokinetic studies: Demonstrating that Inflectra is absorbed, distributed, and eliminated in the body the same way as Remicade
4. Clinical efficacy and safety trials: Head-to-head trials in patients comparing outcomes between Inflectra and Remicade

The FDA approved Inflectra in April 2016 for all of the same indications as Remicade, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Clinical Equivalence Data

The pivotal clinical trial for Inflectra (the PLANETRA study) enrolled patients with rheumatoid arthritis and directly compared Inflectra to Remicade. Results showed:

• Comparable efficacy: ACR20 response rates (a standard measure of improvement in RA) were equivalent between the two groups through 54 weeks of treatment
• Comparable safety: Rates of adverse events, serious adverse events, and infections were similar
• Comparable immunogenicity: The rate at which patients developed anti-drug antibodies was similar for both products

Additionally, the NOR-SWITCH study — a large, independent Norwegian trial — randomized stable patients across all infliximab indications to either continue Remicade or switch to a biosimilar. The study found no meaningful difference in disease worsening, adverse events, or anti-drug antibody development between groups over 52 weeks.

Interchangeability Status

The FDA distinguishes between “biosimilar” and “interchangeable” designations. An interchangeable biosimilar can be substituted at the pharmacy level without prescriber intervention — similar to how a pharmacist can substitute a generic for a brand-name drug.

As of early 2026, Inflectra holds biosimilar status. Regardless of interchangeability designation, many state laws and insurance policies allow or require the use of biosimilars when available. In practice, the switch from Remicade to Inflectra is most often driven by insurance formulary changes rather than pharmacy-level substitution.

The Nocebo Effect: Real and Worth Understanding

Here is something rarely discussed openly enough: when patients switch from a brand-name biologic to a biosimilar, a measurable percentage report new or worsened side effects — even when objective clinical measures show no change in disease activity.

This is the nocebo effect, essentially the opposite of the placebo effect. When a person expects a negative outcome, their body can produce real symptoms. This is not “all in your head” in a dismissive sense — the symptoms are genuinely experienced. The nocebo effect has been well-documented across medicine, and biosimilar switches are a textbook example.

Studies of patients switching from Remicade to biosimilars have found that:

• Patients who were not informed about the switch (in blinded studies) had very low discontinuation rates
• Patients who were informed about the switch (in open-label, real-world settings) had notably higher rates of reported side effects and voluntary discontinuation
• When patients who stopped the biosimilar due to perceived side effects were switched back to Remicade, many did not improve — suggesting the side effects were not caused by the product itself

Practical Advice for Patients Switching

Before the Switch

• Ask your doctor directly: “Do you have concerns about this switch for my specific case?” Most gastroenterologists and rheumatologists are comfortable with biosimilar transitions for stable patients
• Request baseline labs: Having recent inflammatory markers (CRP, ESR) and disease activity scores documented before switching provides an objective comparison point
• Keep a symptom journal: Start tracking symptoms a few weeks before the switch so you have an honest baseline — memory is unreliable when emotions are involved

After the Switch

• Give it a fair trial: At least 2-3 infusions before drawing conclusions, unless a serious adverse reaction occurs
• Continue the symptom journal: Document objectively. Did your daily function actually change, or does the infusion just feel different?
• Report genuine concerns: If you experience new symptoms that were not present before, communicate them to your care team. The goal is not to tough it out — it is to distinguish between real clinical changes and the expected anxiety of change

The reality is that infusion therapy with biosimilars has been used safely by millions of patients worldwide. Many countries, particularly in Europe, transitioned the majority of infliximab patients to biosimilars years ago, and the accumulated real-world evidence has been reassuring.